InSitu Biologics Announces New Leadership
InSitu Biologics today announced that its Board of Directors has appointed Kevin Bassett as President and Chief Executive Officer and member of the Board of Directors effective September 1, 2019 as James Segermark steps down as Chief Executive Officer.
InSitu Biologics has also announces that Dr. Robert Wilson has joined the Board of Directors, effective August 28, 2019.
Kevin Bassett, M.B.A. – President and CEO
Kevin Bassett joined InSitu Biologics in September 2019 as President and CEO. Prior to joining InSitu, Mr. Bassett was General Manager of HLT Medical, a clinical-stage company developing a next-generation heart valve in the field of Transcatheter Aortic Valve Replacement (TAVR). Kevin has also served in a variety of senior executive roles in early-stage medical technology companies over the past twenty years.
Robert Wilson, MD – Member of the Board of Directors
Dr. Wilson has dedicated his professional life to developing new methods for diagnosing and treating heart disease, and to training new physicians. He presently directs the University of Minnesota interventional-cardiology fellowship program and University of Minnesota Physicians clinical cardiovascular services.
Current Report Pursuant to Regulation A
The Company has prepared form 1-U in compliance with the U.S. Securities and Exchange Commission. This document is available to view and we encourage all shareholders to review and save immediately.
The Company is poised for tremendous growth in the coming months as we head into clinical trials with the addition of these new leaders, and we thank you for being a part of our journey.
Regards,
James Knapp
Chairman of the Board
InSitu Biologics
[email protected]
